FDA suspends US testing of Sarepta Duchenne drug over safety concerns

The Food and Drug Administration has suspended testing of an experimental Duchenne muscular dystrophy drug from Sarepta Therapeutics to assess the risk of an adverse reaction that emerged in clinical testing.